USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 18, 2021 | Sep 2021 | $-0.25 | $-0.30 | $-0.19 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 18, 2021 | Sep 2021 | $19.98M | $127.28M | $123.88M |
Burning Rock Biotech's next earnings date is Thursday, Nov 18, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $-0.25 | $-0.25 | $-0.25 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 3 | $-0.91 | $-1.09 | $-0.59 |
| Dec 2022 | 3 | $-0.75 | $-1.07 | $-0.32 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $-0.25 | $-0.19 | $-0.19 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $-0.91 | $-0.62 | $-0.69 |
| Dec 2022 | 0 / 0 | $-0.75 | $-0.47 | $-0.58 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $20.69M | $20.69M | $20.69M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $77.97M | $77.36M | $78.53M |
| Dec 2022 | 4 | $110.97M | $92.79M | $133.85M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 18, 2021 | Sep 2021 | $-0.25 | - | - |
| Aug 31, 2021 | Jun 2021 | $-0.15 | $-0.30 | -107.52% |
| May 25, 2021 | Mar 2021 | $-0.14 | $-0.26 | -81.91% |
| Mar 11, 2021 | Dec 2020 | $-0.16 | $-0.23 | -45.77% |
| Nov 20, 2020 | Sep 2020 | $-0.11 | $-0.19 | -69.62% |
| Aug 11, 2020 | Jun 2020 | $-0.20 | $-0.39 | -95.59% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $-0.48 | $-0.80 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 18, 2021 | Sep 2021 | $19.98M | - | - |
| Aug 31, 2021 | Jun 2021 | $21.41M | $127.28M | 5.94% |
| May 25, 2021 | Mar 2021 | $19.56M | $106.62M | 5.45% |
| Mar 11, 2021 | Dec 2020 | $19.14M | $131.72M | 6.88% |
| Nov 20, 2020 | Sep 2020 | $18.00M | $123.88M | 6.88% |
| Aug 11, 2020 | Jun 2020 | $13.50M | $106.97M | 7.92% |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $64.81M | $429.90M | 563.33% |
BNR's next earnings date is Thursday, Nov 18, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 1 analysts, the average EPS estimation for Burning Rock Biotech's next quarterly earnings is $-0.25, with a low EPS estimation of $-0.25, and a high estimation of $-0.25.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.25, the last 2 month trend is $-0.21, and the 3 month trend is $-0.21.
Based on 1 analysts, the average revenue estimation is $19.98M, with a low revenue estimation of $19.98M, and a high estimation of $19.98M.
Burning Rock Biotech's previous earnings date was Aug 31, 2021 for its fiscal quarter ended Jun 30, 2021.
BNR's earnings per share (EPS) was $-0.30, missing the consensus analysts forecast of $-0.15 by -107.52%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 17.87%, and higher than the same period a year before (Jun 2020) by -21.42%.
Revenues were $127.28M, better than the forecast of $21.41M by 494.48%, up by 19.37% from the previous quarter , and up by 18.98% from the same period last year.
The company reported a net income of $-203.66M.Free cash flow for the quarter was $-119.00M , compared to $-113.14M last quarter and $61.12M a year before.
BNR ended the quarter with $135.58M in total debt, a decrease of -7.18% compared to the previous quarter, and an increase of 152.29% compared to the same quarter a year before.
Burning Rock Biotech's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.
BNR's earnings per share (EPS) was $-0.80.
Revenues were $429.90M, better than the forecast of $64.81M by 563.33%, and up by 12.64% from previous year's revenue.
The company reported a net income of $-407.24M.
Burning Rock Biotech reported a free cash flow of $-153.08M for its fiscal year, compared to $-273.77M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
